All News

The European Respiratory Society International Congress 2021 will feature a wide array of topics, such as gender and respiratory health, the impact of climate change, and management and treatment of chronic cough, but there remains a strong focus on the COVID-19 pandemic, its intersection with respiratory care and treatment of infection.

This new analysis aimed to pinpoint more rigorous predictors of mortality, and it was able to identify “excellent” but not “outstanding” ones, according to the investigators.

This study protocol comes amid a paradigm shift in the treatment of advanced-stagen non–small cell lung cancer (NSCLC) following the emergence and uptake of immunotherapy.

Increasing the dosage of timolol-dorzolamide fixed combination from twice a day to 3 times a day was found to be safe and significantly more effective in reducing intraocular pressure in patients with open-angle glaucoma, although further research on safety may be warranted.

Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.

On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.

HHS establishes the Office of Climate Change and Health Equity; Johnson & Johnson HIV vaccine fails mid-stage trial in sub-Saharan African women; prevalence of overweight and obesity increases significantly in children and adolescents amid the COVID-19 pandemic.

Ezio Bonifacio, PhD, describes the benefits of screening children for type 1 diabetes and what preventive interventions may be possible.

Patients with idiopathic Parkinson disease given Origanum majorana tea in combination with conventional medication exhibited significant improvements in depressive and nonmotor symptom burden vs placebo, although improvement of motor symptoms was not significant.

Researchers characterized new-onset headache, migraine, and tension-type headache (TTH) among patients with confirmed cases of COVID-19.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.

Two people dead after receiving potentially contaminated Moderna COVID-19 vaccines in Japan; Biogen offers its controversial and expensive Alzheimer disease treatment for free to boost prescriptions; COVID-19 infection with the Delta variant may more than double the risk of hospitalization.

The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.

A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.

Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.

In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.

Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

This study is one of only a handful to explore barriers to pulmonary rehabilitation in Iran for patients with chronic obstructive pulmonary disease (COPD).

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

Results of a score-matched analysis showed individuals with hepatocellular cancer reported poor mental health as time progressed after diagnosis.

Research shows higher levels of interleukin 6 in patients with chronic coronary syndrome were associated with an increased risk of cardiovascular events in patients with chronic kidney disease.

The use of potentially inappropriate medications (PIMs) by older adults appeared to be linked to a greater risk of frailty, although the researchers said further work is needed.

Findings from 5 studies presented on day 1 of ESC Congress 2021 indicate that there is still much to be learned on the complex interaction among COVID-19 infection, cardiovascular care, and heart failure.